(Total Views: 588)
Posted On: 03/15/2025 11:40:34 PM
Post# of 155791
Re: sherlock57 #151015
A question for Sherlock, Respert, and anyone else with BP experience:
1. Given that a big pharma's bottom line is it's bottom line, i.e., it's in business to make money and maximize shareholder value, then
2. How likely would it be for a big pharma to act against its own financial best interest and acquire a product like Leronlimab that could, potentially, reduce their revenues by making many of their drugs/treatments obsolete?
I want to maximize our share price. And given LL's proven performance (and Ohm's list), a buyout around $30 seems fair (at this moment). But it would be an absolute disaster to have BP buy our drug . . . and slow walk it into oblivion because it reduced their revenue. So many people could be helped - but would this trump a BP's CEO and BOD desire to keep growing the bottom line?
Is this not a real concern?
1. Given that a big pharma's bottom line is it's bottom line, i.e., it's in business to make money and maximize shareholder value, then
2. How likely would it be for a big pharma to act against its own financial best interest and acquire a product like Leronlimab that could, potentially, reduce their revenues by making many of their drugs/treatments obsolete?
I want to maximize our share price. And given LL's proven performance (and Ohm's list), a buyout around $30 seems fair (at this moment). But it would be an absolute disaster to have BP buy our drug . . . and slow walk it into oblivion because it reduced their revenue. So many people could be helped - but would this trump a BP's CEO and BOD desire to keep growing the bottom line?
Is this not a real concern?
(5)
(3)
